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Abstract 
 
In this study, we investigated the potential molecular and immunological differences 
resulting from production of the recombinant fusion proteins (Hybrid-1, comprising of 
the immunodominant antigens Ag85B and ESAT-6 from Mycobacterium 
tuberculosis) in two different expression systems, namely M. smegmatis and 
Escherichia coli. The fusion protein was successfully expressed and purified from 
both bacterial hosts and analyzed for any host-dependent post-translational 
modifications that might affect the immunogenicity of the antigen. We investigated 
the immunogenicity from both from E. coli-derived Hybrid-1 fusion and M. 
smegmatis-derived Hybrid-1 fusion in a murine vaccination model, together with a 
reference standard Hybrid-1 (expressed in E. coli) from the Statens Serum Institut. No 
evidence of any post-translation modification was found in the M. smegmatis-derived 
Hybrid-1 fusion protein, nor were there any significant differences in the T-cell 
responses obtained to the three antigens analyzed. In conclusion, the Hybrid-1 fusion 
protein was successfully expressed in a homologous expression system using M. 
smegmatis and this system is worth considering as a primary source for vaccination 
trails, as it provided protein of excellent yield, stability and free from 
lipopolysaccharide. 
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1. Introduction 
 
Tuberculosis (TB) is still a major cause of morbidity and mortality in the world today. 
Currently, it is estimated that 2-3 million deaths occur worldwide from active TB and 
there are 8-10 million new cases per year, whilst a third of the world population are 
latently infected with the causative agent, Mycobacterium tuberculosis (Dye, 2006; 
Maher et al., 2007). During latency, M. tuberculosis is able to survive and persist as 
an intracellular pathogen for years, by being able to modulate phagosomal maturation, 
preventing phagosomal-lysosome fusion and reducing acidity within the phagosome 
(Gupta et al., 2012; Russell, 2001). M. tuberculosis also has significant interaction 
with components of the innate immune system e.g. toll-like receptors (TLRs), 
complement and lung surfactant proteins SP-A and SP-D, which play important roles 
in shaping adaptive immunity to TB infection in the host (Tsolaki, 2009).  The only 
licensed vaccine being used currently against M. tuberculosis is M. bovis Bacillus 
Calmette-Guerin (BCG), which has been used worldwide since the early 1900s. 
Whilst BCG has been shown to be protective against childhood forms of TB, its 
efficacy against adult active TB varies greatly, ranging from 0 to 85% (Andersen and 
Doherty, 2005; Fine, 1995). Improved vaccines are urgently needed, particularly to 
target the global epidemic of adult active TB, which is the most infectious form of the 
disease (Hanekom et al., 2008). During the last few years, a number of new candidate 
vaccines against TB have now been trailed, with several vaccines showing improved 
efficacy (Andersen, 2007). Among these candidates is the fusion protein Hybrid-1 or 
H1, which is based on the immunodominant antigens Antigen 85B (Ag85B) and the 
Early Secretory Antigenic Target (ESAT-6) from M. tuberculosis. The Hybrid-1 
fusion protein is at the forefront of candidate vaccines against TB and has been 
extensively tested in a number of studies (Agger et al., 2008; Dietrich et al., 2007; 
Langermans et al., 2005; Olsen et al., 2004; van Dissel et al., 2010; van Dissel et al., 
2011; Weinrich Olsen et al., 2001). A recent variant has also been fused to the latency 
associated protein Rv2660c (H56) that promises efficacy against pre- and post 
exposure (latent) TB (Aagaard et al., 2011).  The majority of tested vaccine candidate 
antigens are heterologously expressed in various strains of the common laboratory 
organism Escherichia coli (E. coli), in spite of the fact that the protein folding and 
post-translational modification mechanism in the pathogen might be very different, 
compared to the host mycobacterium. Protein lacking the native mycobacterial milieu 
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and modifications may be less immunologically active (Triccas et al., 1996). Post-
translational modifications such as methylation have been shown to alter the 
immunogenicity of recombinant proteins when comparisons were made between 
native mycobacterial protein versus the recombinant protein expressed from E. coli 
(Menozzi et al., 1998; Pethe et al., 2002; Temmerman et al., 2004). The purification 
of native proteins from M. tuberculosis or M. bovis BCG for biochemical and 
immunological analysis is a complex and laborious process, often resulting in poor 
yields of protein (Delogu and Brennan, 1999; Menozzi et al., 1996). Recombinant 
expressions systems have been developed recently that can be used in fast-growing 
non-pathogenic mycobacteria. These systems have made use of modified 
mycobacterial plasmids that have been engineered to over-express protein, via the 
hsp60 promoter (Curcic et al., 1994; Delogu et al., 2004; DeMaio et al., 1997; 
Dziadek et al., 2002; O'Donnell et al., 1994). Inducible systems for mycobacteria 
expression have also been developed, using tetracycline induction, which provide 
controlled amounts of protein expression (Blokpoel et al., 2005; Carroll et al., 2005; 
Ehrt et al., 2005; Triccas et al., 1998). Using such systems has potential in producing 
recombinant proteins with features that are native to those in M. tuberculosis, free 
from lipopolysaccharide (LPS) contamination, thus facilitating its use as an optimum 
vaccine candidate or new diagnostic marker (Masungi et al., 2002).  
 
The aim of the present study was to develop a system of expression in M. smegmatis 
that would allow the expression of antigens from M. tuberculosis and their efficient 
purification, with the resultant recombinant protein resembling the native antigen. We 
therefore describe the expression of the Hybrid-1 fusion protein in E. coli and M. 
smegmatis, using mycobacterial-shuttle plasmid vectors (Blokpoel et al., 2005; Wiles 
et al., 2005). The expresssion vector used here contains the tetRO region from the 
Corynebacterium glutamicum TetZ, making expression of genes cloned downstream 
of tetRO responsive to tetracycline We demonstrate the purification of the 
recombinant Hybrid-1 proteins from both bacterial hosts and analysis of their 
biochemical and immunological characteristics, in order to determine whether there 
are any differences in their immunogenicity.  
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2. Materials and Methods 
 
2.1 Bacterial strains and growth conditions 
 
Mycobacterium smegmatis mc
2
-155 was grown at 37
o
C, in Middlebrook 7H9 liquid 
broth or on Middlebrook 7H11 solid media, prepared according to the manufacturer’s 
instructions, and supplemented with OADC (Difco), 0.08% glycerol and 0.05% 
Tween-80 (Sigma). All Escherichia coli strains were grown on LB-agar plates or in 
LB broth. When needed, kanamycin was added at a final concentration of 50μg/ml for 
E. coli and hygromycin was added at a concentration of 50 μg/ml for M. smegmatis.  
 
2.2 Cloning of Hybrid1fusion into mycobacteria shuttle vectors 
 
The pMCT6 plasmid containing the gene fusion Ag85B and ESAT-6 (Hybrid-1) was 
constructed as previously described (Weinrich Olsen et al., 2001). The hybrid-1 
fusion was amplified from pMCT6 using, Ag85B-HB-forward primer (5’-CGC GGA 
TCC ATG CAC CAC CAC CAC CAC CAC TTC TCC CGG CCG GGG CTG CC-
3’) and ESAT-6-SpeI-reverse primer (5’-GGA CTA GTC TAT GCG AAC ATC CCA 
GTG ACG TTG CCT TC-3’). The forward primer contained a BamHI restriction site 
and the reverse primer contained a SpeI restriction site (underlined). The forward 
primer also contains a HIS-tag to facilitate purification. Amplification was carried out 
for 30 cycles with denaturation at 94
o
C for 1min, annealing at 55
o
C for 1 min and 
extension at 72
o
C for 90 secs, using Biolase Taq polymerase (Bioline Reagents, UK). 
PCR products were purified (Qiagen, UK) and digested by BamHI and SpeI enzymes 
(New England Biolabs, UK) and positionally cloned into the tetracycline-inducible 
vector pMind, described previously (Blokpoel et al., 2005) and the pSHKLx1 shuttle 
vector, (Wiles et al., 2005). Both plasmids pMind and pSHKLx1 are E.coli–
mycobacteria shuttle plasmids containing kanamycin and hygromycin selection 
markers. The pSHKLx1 also contains the constitutively expressed promoter hsp60 
from M. tuberculosis H37Rv (Wiles et al., 2005). The luxAB reporter genes in 
pSHKLx1 were replaced with the Hybrid-1 fusion, via the BamHI and SpeI sites. 
Both pMind (Hybrid-1) and pSHK (Hybrid-1) were transformed into E. coli strains 
DH5a and BL21 (Invitrogen, UK), using the CaCl2 method (Sambrook, 2000) and 
pSHK (Hybrid-1) expressed in E. coli strain BL21 (Invitrogen, UK). Vectors pMind 
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(Hybrid-1) and pSHK (Hybrid-1) were introduced into M. smegmatis by 
electroporation, using the protocol previously described (Parish and Stoker, 1998). 
 
2.3. Expression conditions 
 
For M. smegmatis starter cultures were set up consisting of pMind(Hybrid-1) 
transformants in triplicate 20 ml cultures of Middlebrook 7H9 liquid broth, 
supplemented with OADC, 0.08% glycerol and 0.05%Tween-80 at 37
o
C, in 125 ml 
conical flasks and shaken at 200 rpm in an orbital shaker. Mycobacterial cultures were 
then sub-cultured at log phase, in 800ml in 2L flasks overnight. Induction of 
expression was achieved by adding 20ng/ml of tetracycline. Cells were harvested after 
4 hours of induction. For E. coli, starter cultures were performed using triplicate 20 ml 
cultures in LB-broth, in 125 ml conical flasks, shaken at 200 rpm in an orbital shaker. 
E. coli cultures were then sub-cultured at log phase in 400ml of 1L LB and incubated 
overnight at 37
o
C before harvesting. Samples were processed for protein purification 
as described below. 
 
2.4. Protein purification 
 
M. smegmatis cultures were harvested at 4400×g and the pellet washed twice with ice 
cold PBS (0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M 
sodium chloride, pH 7.4). Cells were resuspended in PBS containing 0.05% Tween 80 
(Sigma-Aldrich), protease inhibitor (P-8849, Sigma-Aldrich), lysozyme (Sigma-
Aldrich, at a final concentration of 2.4 mg/ml) and incubated on ice for 30 min. Cells 
were disrupted twice with a cell disrupter French press machine (Constant Systems 
Ltd) at a pressure of 1.1×108 Pa. E. coli cultures were harvested at 10,000 x g for 10 
min and the pellet resuspended in BugBuster Reagent (5 mL/g wet pellet) (Novagen), 
Benzonase nuclease (Novagen) (25 U per 1 mL BugBuster), Lysozyme (Sigma) (5 
KU/g wet pellet) and protease inhibitor (P-8849, Sigma-Aldrich). The cell suspension 
was then incubated for 30 mins at room temperature with gentle shaking. Insoluble 
debris was removed by centrifugation at 16,000 x g for 20 min at 4C. 
 
Lysates from both M. smegmatis and E. coli were then size-fractionated using gel-
filteration S-100 and S-10 spin columns (Amicon, Millipore) to exclude protein 
outside the range of 10-100kDa. This fractionated lysate was then passed over a 1 ml 
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HisTrap HP Ni-affinity sepharose column (GE Healthcare) and eluted with 500mM 
imidazole. Eluted fractions were analyzed on SDS-PAGE and Coomassie staining. 
Positive fractions were then further purified by FPLC (AKTA, GE healthcare) by 
loading onto a 1 ml HisTrap HP column (GE Healthcare). For the purification a 
gradient of imidazole concentration was used, from 10 mM (wash buffer, 20 mM 
sodium phosphate, 0.5 M NaCl and 10 mM imidazole, pH 7.4) to 0.5 M (elution 
buffer, 20 mM sodium phosphate, 0.5 M NaCl and 0.5 M imidazole, pH 7.4). Eluted 
fractions were tested for the presence of the Hybrid-1 fusion protein, by 
immunoblotting. Protein concentration of the final pooled purified sample of hybrid 1 
was determined using the BCA method (Piercenet). H1 (EC, SSI) was produced and 
purified as previously described (Weinrich Olsen et al., 2001). 
 
 
2.5. SDS-PAGE and immunoblots 
 
Cell fractions were analyzed with the PhastSystem (Amersham) using 12% SDS-
PAGE gel and transfer to nitrocellulose membrane (Laemmli, 1970). This was further 
interrogated using anti-His tag (Invitrogen), anti-Ag85-TD17 and anti-ESAT-6 -
HYB76-8 antibodies (obtained from SSI).  
 
2.6. Post-translational modification assays 
 
Protein fractions on Immunoblots were analyzed for glycosylation using the GLYCO-
PRO kit (Sigma-Aldrich) and for phosphorylation by the PhosDecor kit (Sigma-
Aldrich). 
 
2.7. Mass spectrometry 
 
Purified proteins were excised from SDS-PAGE gels and subjected to MALDI-TOF 
mass spectrometry, using MASCOT to identify the peptides. This was performed at 
Hammersmith Hospital, Imperial College, London. 
 
2.8. Immunization study 
 
Immunogenicity of the M. smegmatis derived (H1 (MS, IC)) and E. coli derived (H1 
(EC, IC)) Hybrid1 proteins were tested, together with an E. coli Hybrid-1 preparation 
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previously published (H1 (EC, SSI)) (Weinrich Olsen et al., 2001). The experiments 
on all three antigens were done using the methods outlined recently (Agger et al., 
2008). Briefly, mice were immunized three times, intramuscularly, at 3-week 
intervals, using a volume of 200 μl. All mice received a dose of adjuvant (250μg 
Dimethyldioctadecylammonium (DDA)/50 μg a,a’-trehalose 6,6’-dibehenate (TDB)) 
with 2μg of Hybrid1 antigen preparation.  
 
2.9. Splenocyte cultures 
 
Mice were rested for 3 weeks following the third immunisation, after which they were 
culled and spleen harvested. Cultures of splenocytes were obtained by homogenizing 
the organ into complete RPMI (RPMI 1640 supplemented with 5 x 10
-5
 M 2-
mercapthoethanol, 1 mM glutamine, 1% penicillin-streptomycin, 1% HEPES and 
10% fetal calf serum all from Gibco (Invitrogen, Carlsbad, CA). Subsequently, cells 
were washed twice and adjusted to a final concentration of 2.6 x 10
5
 cells/well in a 
total volume of 200 μl/well. Splenocytes were re-stimulated with purified antigen at 
5µg/ml, whereas Concanavalin A (Con A) at a concentration of 5µg/ml was used as a 
positive control for cell viability and medium used as a negative control. Ag85B and 
ESAT-6 antigen peptides were tested (E6-P1 and 85B-P63), as well as recombinant 
Ag85B, the ESAT-6 dimer protein dESAT-6, and the three hybrid1 antigens (H1 (EC, 
IC), H1 (MS, IC) and H1 (EC, SSI). Culture supernatants were harvested from 
parallel cultures after 72 h of incubation for the investigation of IFN-γ by ELISA 
performed as previously described (Dietrich et al., 2007).  
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3. Results 
 
3.1. Successful expression of the Hybrid-1 fusion protein in E. coli and M. 
smegmatis 
 
The Hybrid-1 (Ag85B-ESAT-6) fusion gene fragment was successfully cloned into 
the vectors pMind and pSHK, with an additional histidine tag at the N-terminal end of 
the protein. Cloning the Hybrid-1 fusion protein into the plasmid pMind allowed the 
controlled expression of this protein in M. smegmatis under the tetracycline inducible 
promoter. The histidine tag facilitated purification. Expression of the Hybrid-1 fusion 
protein is shown in Figure 1. In both E. coli and M. smegmatis hosts, the expected size 
of the 35 KDa Hybrid-1 fusion proteins was obtained. In E. coli, expression did not 
require induction, since the pSHK (Hybrid-1) was under the control of the constitutive 
promoter hsp60. After 1hr, expression was detected and this was increased after 
overnight incubation. In M. smegmatis, the expression of the Hybrid-1 fusion was also 
detected after just 1 hr of induction with 20ng/ml of tetracycline. There did not appear 
to be significant increase in the levels of expression after 4hrs. The 35KDa band 
obtained was confirmed to be the Hybrid-1 fusion protein by immunoblotting, using 
anti-His tag antibody (results not shown). 
 
3.2. Purification of the histidine-tagged Hybrid-1 fusion protein in E. coli and M. 
smegmatis 
 
We next determined whether our expression of the Hybrid-1 fusion protein in E. coli 
and M. smegmatis allowed for the efficient purification of the 35KDa protein using 
the histidine tag on its N-terminus. A similar approach has been used before to purify 
proteins from mycobacteria successfully, without the histidine tag compromising the 
function or immunogenicity of the protein (Crowe et al., 1994; Triccas et al., 1998). 
Lysates of the M. smegmatis were obtained using a French Press cell disrupter and 
then size fractionated. These fractions were then past over a HIS-Trap column with 
varying amounts of imidazole (10mM, 20mM and 50mM), before bound protein was 
washed off with 250mM of imidazole. The same process was also used for the E. coli 
Hybrid-1 fusion protein purification, except that E. coli cells were disrupted using 
Bugbuster lysis buffer. Purified fractions from the His-trap from E. coli and M. 
smegmatis were run on a 12% SDS-PAGE gel, in order to examine the purity of the 
protein extracts. Although a distinct 35KDa band was observed (confirmed by 
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immunoblot with anti-HIS tag antibody), there were also contaminating proteins still 
present (results not shown). Pooled fractions of HIS-trap purified protein were 
therefore subjected to further standard gel filtration fractionation, using an automated 
AKTA FPLC system, in order to remove contaminating host proteins (Figure 2). The 
presence of HIS-tagged fusion protein was confirmed using anti-HIS tag antibody. 
The yield of protein obtained for the M. smegmatis-derived Hybrid-1 is 5mg/L of 
culture, whilst for E. coli-derived Hybrid-1 it was 0.5mg/L of culture. 
 
 
3.3. Characterization of the Hybrid-1 fusion protein in E. coli and M. smegmatis 
 
Anti-Ag85B or ESAT-6 specific monoclonal antibodies of well-defined specificity 
(obtained from the SSI, Figure 3), were used to identify recombinant proteins via 
immunoblotting. This showed that the M. smegmatis-derived Hybrid-1 fusion protein 
was intact (Figure 4). However, using the same monoclonal antibodies, the E. coli 
Hybrid-1 protein was shown to have lost the ESAT-6 epitope recognised by the 
monoclonal antibody HYB76-8 (Figure 4B). Positive signals for monoclonal antibody 
TD17 indicated that a full length Ag85B was present. The epitope for HYB76-8 has 
been mapped to the start of the ESAT-6 molecule suggesting that the whole of the 
ESAT-6 portion has been deleted from the E. coli-derived Hybrid-1. 
 
In order to further investigate this truncation of the E. coli-derived Hybrid-1, we 
carried out MALDI-TOF mass spectrometry, using MASCOT to identify the peptides 
obtained. Peptides were obtained that were identified as Ag85B (Figure 3), being as 
follows: MS-pep1 (VQFQSGGNNSPAVYLLDGLR) and MS-pep2 
(AADMWGPSSDPAWERNDPTQQ). No ESAT-6 peptides were identified and this 
was consistent with the pattern of antibody staining obtained (Figure 4B). 
 
Post-translational modifications were sought using commercially available gel 
staining kits, but there was no evidence of either glycosylation or phosphorylation in 
the hybrid-1 fusion from M. smegmatis (results not shown). 
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3.4. Immunogenicity of the Hybrid-1 fusion protein in E. coli and M. smegmatis 
in mice 
 
In order to compare the immunogenicity of the M. smegmatis- and E. coli-derived 
Hybrid-1 proteins, all three antigens were evaluated using 3 subcutaneous injections 
at 3 weeks intervals of 2µg of protein in DDA-TDB adjuvant CAF01. In addition, a 
reference Hybrid-1 fusion also expressed in E. coli and obtained from the SSI (H1, 
(EC, SSI)) was included for comparison. Animals were rested for 3 weeks after the 
third immunization, after which they were culled and the spleens were harvested. 
Splenocytes were re-stimulated with antigen at 5µg/ml for 72 hours, and then IFN-γ 
levels in the culture supernatants were measured by ELISA in the culture 
supernatants. A range of Ag85B and ESAT-6 peptides were tested, as well as the 
whole antigens from the various sources, and the levels of IFN-γ obtained are shown 
for a selection (Figure 5). There was little difference in the pattern of reactivity 
observed from all three proteins analyzed, with even the truncated protein (H1 (EC, 
IC)) showing very similar levels of reactivity to the two full length proteins H1 (MS, 
IC) and H1 (EC, SSI).  Immunisation with all three H1 proteins led to recognition of 
the Ag85B recombinant protein and the previously identified CD4 epitope 
QDAYNAAGGHNAVFN, represented by the Ag85B-P63 peptide (Bennekov et al., 
2006). However, the Hybrid-1 protein from E. coli (H1 (EC, IC)), missing the ESAT-
6 portion of the fusion, did not react in the stimulation assay to either the ESAT-6 
dimer (dESAT-6), or to the peptide E6-P1, which maps to the deleted region. This 
further confirms the loss of this region in the fusion protein. 
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4. Discussion 
 
Expression of recombinant proteins in fast-growing non-pathogenic mycobacteria has 
been used extensively, as a result of the recent developments in Mycobacterial shuttle 
vectors.  In the present study, our goal was to express recombinant fusion protein 
Hybrid-1 (Ag85B-ESAT-6) in the mycobacterial host M. smegmatis to test if 
expression in a mycobacterial host resulted in a vaccine candidate fusion protein with 
intact or improved immunogenicity as well as possible post-translational changes. We 
have successfully cloned the Hybrid-1 fusion into a mycobacterial vector pMind and 
expressed the protein in M. smegmatis, using a Tetracycline-inducible expression 
system. The yield obtained was 5mg/L of M. smegmatis-derived Hybrid-1 protein, 
compared to 0.5mg/L of E. coli-derived Hybrid-1, giving sufficient soluble protein for 
further analysis and animal trials. We have also demonstrated successful expression 
and purification of the Hybrid-1 fusion protein by cloning it into the plasmid pSHK, 
with the constitutively expressed promoter hsp60. 
 
M. smegmatis protein reacted with all the available Hybrid-1 component specific 
antibodies. However, the E. coli-derived Hybrid-1 protein lacked the ESAT-6 epitope 
recognized by the antibody HYB76-8, and MALDI-TOF analysis provided 
confirmation that part of the Hybrid-1 molecule had been lost. The mechanism for this 
is unknown, but may have involved some post translation cleavage of the protein 
within the host E. coli. It is also possible that the overnight expression of the soluble 
protein in E. coli led to protein cleavage of the ESAT-6 fragment. In the original 
report describing the expression of the Hybrid-1 fusion, the authors used E. coli XL-1 
blue (Weinrich Olsen et al., 2001), which differs in genotype to E. coli BL21 and may 
give some insights into how the truncation of Hybrid-1 occurred. It is possible that E. 
coli BL21 has cleaved the expressed fusion in order to keep the protein soluble. It is 
interesting to note that truncated forms of ESAT-6 have been identified from M. 
tuberculosis culture filtrate, showing loss of 11 residues at the C-terminal end of the 
antigen, but this did not affect its binding to the 10 KDa culture filtrate protein 
(CFP10) (Okkels et al., 2004). 
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No evidence was found of either phosphorylation or glycosylation in the M. 
smegmatis-derived Hybrid-1fusion protein. This finding is also reflected in the data 
from the vaccination experiments, where there were no significant differences in the 
T-cell responses in vaccinated animals, apart from those differences consistent with 
the loss of ESAT-6 from the E. coli-derived protein. The E. coli-derived Hybrid-1 
control protein from the SSI, and M. smegmatis-derived fusion protein from this study 
showed identical reactivity. The present study did not analyse the Hybrid-1 fusion 
proteins for methylation and acetylation, but given the similarity in the immune 
responses following vaccination this is unlikely to play a major role in 
immunogenicity. Methylation of the M. tuberculosis heparin-binding hemagglutinin 
(HBHA) is essential for effective T-cell immunity to this antigen (Temmerman et al., 
2004). Moreover, acetylated and non-acetylated forms of ESAT-6, show differential 
binding to the antigen CFP10 (Okkels et al., 2004). 
 
In M. bovis BCG as a host, expression of recombinant protein was found to be 
significantly lower with the inducible tetA (present in pMind), than the strong 
mycobacterial promoter hsp60 (Blokpoel et al., 2005). However, the same study also 
found that the magnitude of induction of tetA was approximately 50 times higher in 
fast-growing mycobacteria (M. smegmatis), than slow growing mycobacteria (M. 
tuberculosis, and M. bovis BCG) (Blokpoel et al., 2005). The inducible pMind system 
described in the present study may not be suitable for over-expression of recombinant 
antigens for high yields, but is better suited when controlled expression is required in 
a situation where a gene product may be toxic to the mycobacterial host cell. A better 
regulated version of this system has recently been published (Williams et al., 2010). 
Similarly, the inducible pMind system provides a useful system to study 
mycobacterial pathogenesis, by regulating the expression of mycobacterial genes, 
using antisense mRNA to knockdown specific gene products (Blokpoel et al., 2005).  
It is also preferred to express recombinant mycobacterial proteins in mycobacterial 
hosts, since a number of proteins are post-translationally modified in mycobacteria 
and therefore cannot be expressed as a native protein in the E. coli host. 
 
Previously, other expression systems have been used, that contain alternative 
promoters such as the M. smegmatis acetamidase promoter and the β-lactamase 
promoter of M. fortuitum (Triccas et al., 1998).  
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There have been studies showing the advantage of recombinant proteins expressed 
and purified from mycobacterial hosts versus to E. coli (Garbe et al., 1993; Roche et 
al., 1996; Triccas et al., 1998; Triccas et al., 1996), with one study showing that a 
recombinant M. leprae antigen expressed in M. smegmatis was only recognized by the 
antisera from leprosy patients (Triccas et al., 1996).  
 
The addition of the HIS-tag allows for a simple and effective purification of the 
fusion. The HIS-tag on the Hybrid-1 fusion of both the E. coli-derived protein and M. 
smegmatis protein also does not appear to have affected the confirmation of the 
protein and there is little difference in the T-cell responses, when compare to the E 
coli derived Hybrid-1 protein from the SSI, which lacks the HIS-tag. A similar finding 
was also demonstrated in the analysis of another mycobacterial antigen (Triccas et al., 
1996). 
 
In conclusion, we have provided proof of principle evidence that vaccine candidates 
from M. tuberculosis can be expressed in a surrogate mycobacterial host and 
sufficient protein obtained for immunological and biochemical analysis. The 
expression systems described in this study could be used to test other M. tuberculosis 
antigens in preparation for obtaining an optimal TB vaccine, facilitating the analysis 
or their structure, function and antigenicity. 
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Figure Legends 
 
Figure 1: Expression of 35kDa Hybrid-1 gene fusion in E. coli (Ec) and M. 
smegmatis (Ms).  Lysates run on a 12% SDS-PAGE gel with Coomassie staining: 
Lane 1: Protein standard marker; lane 2, E. coli only; lane 3, M. smegmatis habouring 
pMind(Hybrid-1) in the absence of tetracycline; lanes 4 and 5, E. coli harbouring 
pSHK(Hybrid-1) and harvested after 1hr and 16hrs of growth respectively; lanes 6 
and 7, M. smegmatis habouring pMind(Hybrid-1) in the presence of 20ng/ml of 
tetracycline, for 1 hour and 4 hours respectively. Comparable amounts of bacterial 
extracts were loaded in each well. 
 
 
Figure 2: Purification of Hybrid-1 fusion protein from M. smegmatis using 
FPLC. Semi-purified fractions from HisTrap HP Ni-affinity sepharose column were 
further purified using FLPC to remove contaminating proteins. Three fractions (Lanes 
1, 2 and 3) were obtained and confirmed to be the Hybrid-1 fusion using 
immunoblotting with the Anti-HIS monoclonal antibody.  Results shown are from M. 
smegmatis Hybrid-1. The E. coli Hybrid-1 was also purified using this method (not 
shown). 
 
Figure 3: Schematic representation of the Hybrid-1 fusion protein. The fusion is 
made up of the antigen 85 and ESAT-6 proteins of M. tuberculosis. There is a 
histidine-tag at the N-terminal end to aid purification. The position and name of the 
monoclonal antibodies used for characterization are shown; together with the peptide 
sequences resolved using mass spectroscopy (MS-pep1 and MS-pep2). 
 
Figure 4: Purified Hybrid-1 fusion protein from E. coli and M. smegmatis 
characterized by immunoblotting. A) Lysates run on a 12% SDS-PAGE gel with 
Coomassie staining: Lane 1: Protein standard marker; lane 2, E. coli  Hybrid-1 
protein; lane 2 M. smegmatis Hybrid-1 protein.  B) Immunoblots of SDS-PAGE gel: 
Lanes 1 and 2, E. coli Hybrid-1 M. smegmatis Hybrid-1 probed with HYB76-8 
antibody, respectively;   lanes 3 and 4, E. coli Hybrid-1 M. smegmatis Hybrid-1 
probed with TD17 antibody, respectively; lanes 5 and 6, E. coli Hybrid-1 M. 
smegmatis Hybrid-1 probed with Anti-HIS antibody, respectively.     
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Figure 5: Comparison of the immunogenicity of the E. coli and M. smegmatis 
derived Hybrid-1 proteins. Proteins E. coli Hybrid-1 and M. smegmatis Hybrid-1 
were compared with an E. coli Hybrid-1 prepared at the SSI, Denmark.  C57BL/6J 
Mice were injected three times (SC) at 3 weeks intervals using 2µg of protein in 
CAF01 adjuvant. Three weeks after the third immunisation, animals were culled and 
spleens harvested. Splenocytes were re-stimulated with antigen at 5µg/ml for 72 
hours, and then IFN-γ levels were measured by ELISA in the culture supernatants, 
using Ag85B and ESAT-6 peptides as well as Ag85B, the ESAT6 dimer protein and 
the H1 antigens from the various sources. H1(EC, IC) : E. coli Hybrid-1;  H1 (MS, 
IC): M. smegmatis Hybrid-1; H1(EC, SSI) : E. coli Hybrid-1 from SSI, Denmark; Con 
A: Concanavalin A. Results are presented as the mean value ± S.E.M. of 3 mice. 
20 
 
Figure 1: 
 
21 
 
Figure 2: 
 
22 
 
Figure 3: 
 
23 
 
Figure 4: 
 
24 
 
Figure 5: 
 
